Leverages molecular profiling to identify genetic and epigenetic alterations in cancer. Cancer Panels detect hereditary (e.g., BRCA1/2) and somatic mutations, while OncoMaster.AI uses AI-driven analytics to predict drug responses in colorectal cancer by assessing tumor mutational burden (TMB) and microsatellite instability (MSI). Tumor-informed ctDNA assays monitor minimal residual disease (MRD) via liquid biopsies, offering real-time insights into treatment efficacy and recurrence risk.
Take the first step toward better health — send us your inquiry today and discover personalized insights for a healthier future.
"Frankly speaking, the experience was the first time I dealt with them. They were very quick to respond. They made an appointment for me at home on their appointment, and there was no delay. The result was not delayed exactly as they said, 7 days. God willing, I wish them success, Lord."
© Copyright 2025 Novo Genomics. All Rights Reserved